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Abstract 
Background: To assess the effects of  Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary 
function (in MucilAir™Nasal cells).
Methods: MucilAir™Nasal, a three-dimensional organotypic airway tissue model (with different cell types), was 
treated with  Rhinosectan® (30 µl) or with a control (saline solution). The effects of  Rhinosectan® were evaluated at 
15 and 60 min post-exposure by: measurement of the cilia beating frequency (Hz), mucin detection (Enzyme-Linked 
Lectin Assay—ELLA), mucociliary clearance (µm/s) and phagocytosis assay (fluorescence).
Results: Exposure of MucilAir™ to  Rhinosectan® did not alter the cilia beating frequency at 15 and 60 min post-expo-
sure (diluted and undiluted). Exposure to  Rhinosectan® (undiluted) during 60 min increased mucociliary clearance 
(93.3 ± 2.1 µm/s vs. 80.9 ± 1.8 µm/s; p < 0.01) and phagocytic activity (1.89-fold increase) in comparison with saline 
solution. Moreover, a significant decrease in mucin concentration was observed after 15 min of exposure (171.4 ng/ml 
vs. 306.5 ng/ml; p < 0.01) and at 60 min post-treatment (242.7 ng/ml vs. 339 ng/ml; p < 0.05).
Conclusions: The application of  Rhinosectan® to nasal epithelial cells does not impair ciliary movement, enhances 
mucociliary clearance and facilitates phagocytosis while reducing mucin secretion, which are optimal properties for 
the management of rhinitis and associated conditions.
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Background
Nowadays, there is growing interest in understanding the 
role played by the disruption of the mucosal epithelial 
barrier in the pathogenesis of a wide variety of diseases. 
Exposure to bacterial pathogens and their products, 
allergens, pro-inflammatory compounds or environmen-
tal particles have been identified to have role, together 
with the emerging evidence supporting the relevant role 
of microbiota changes (known as dysbiosis), promoting 
inflammatory conditions and leading to the development 
of diseases [1–4]. In this regard, there is a need to under-
stand the specific causes of mucosal disruption of each 
mucosal membrane and to prevent and/or counteract 
their damaging effects on the mucosal membranes [1, 5].
In the case of respiratory diseases, understanding the 
regulation of airway epithelial barrier function is becom-
ing a new frontier in respiratory allergic diseases, such 
as asthma and rhinitis, and also in respiratory infections 
(such as viral infections), thus opening up potential new 
therapeutic targets for respiratory diseases [1, 5, 6]. This 
is also in agreement with current recommendations of 
ARIA (allergic rhinitis and its impact on asthma) guide-
lines to avoid when possible the contact with allergens 
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and other triggering factors as an integral part of the 
management strategy for rhinitis [5, 7, 8]. This could also 
be extended to other respiratory allergic and infectious 
diseases, based on current knowledge of the mechanisms 
by which pathogens disrupt epithelial structure and func-
tion, allowing better understanding of the associations 
between respiratory infections, airway inflammation and 
allergen sensitization [6].
In the particular case of allergic rhinitis, findings from 
basic science and epidemiological studies show that this 
disease is a part of a systemic inflammatory process 
and is associated with other inflammatory disorders of 
mucous membranes [9], including asthma, rhinosinusi-
tis and allergic conjunctivitis [9]. In order to prevent or 
decrease this inflammatory process, non-pharmaco-
logical approaches that restore the barrier integrity are 
becoming of great interest [5, 8].
In this regard,  Rhinosectan® spray (Noventure, SL, 
Barcelona, Spain), a medical device containing xyloglu-
can as the main ingredient, was developed to restore the 
physiological functions of the nasal epithelial mucosa 
by forming a film that protects the mucosa from differ-
ent pathogens and allergens.  Rhinosectan® is specifically 
formulated for the control and reduction of symptoms 
related to rhinorrea and sinus congestion due to differ-
ent etiologies, such as rhinitis (seasonal, perennial aller-
gic, infectious or vasomotor rhinitis), sinus congestion 
due to cold or flu; and as symptomatic relief associ-
ated to the treatment of nasal polyps and acute sinusi-
tis.  Rhinosectan® spray has been shown to significantly 
reduce rhinorrhea, itching, TNSS (total nasal symptom 
score) and the severity of rhinosinusitis, in comparison 
with physiological saline spray, in patients with rhinosi-
nusitis, after nasal administration during 2 weeks [10].
Xyloglucan is a natural hemicellulose extracted from 
the seeds of the tamarind tree (Tamarindus indica), 
which forms a bio-protective film, avoiding the contact 
with pathogenic bacteria, bacterial products, allergens 
or pro-inflammatory compounds as shown in in  vitro 
and in  vivo studies [1, 5, 11–15]. In a recent in  vitro 
study on a MucilAir™ airway tissue model,  Rhinosectan® 
spray protected cell tight junctions (producing increases 
in TEER—trans-epithelial electrical resistance) and 
preserved the paracellular flux, even after exposure to 
pro-inflammatory compounds (TNF-α and LPS from 
Pseudomonas aeruginosa 10). Results obtained by confo-
cal immunofluorescence microscopy also highlighted the 
barrier properties of  Rhinosectan®, with low affectation 
of the tight junction proteins zonula occludens-1 and 
occludin, in comparison with the glucocorticoid budeso-
nide [5].
As a continuation of this study, and taking into account 
the potential adverse effects of first-line drugs for the 
treatment of rhinitis and related diseases, such as corti-
costeroids and antihistamines, on the nasal structure and 
ciliary function [16], this study has assessed the effects 
of  Rhinosectan® on nasal functioning in a MucilAir™ 
airway tissue model (in terms of cilia beating frequency, 




MucilAir™Nasal is a morphologically and functionally 
differentiated three-dimensional model of nasal epithelial 
tissue (Epithelix Sàrl, Geneva, Switzerland) [17], where 
the epithelia are cultivated on microporous filters at the 
air–liquid interface (ALI). Typical ultra-structures of 
the human airway epithelium are observed: tight junc-
tions, cilia, basal cells and mucous cells. The ALI allows 
direct administration of an aerosol onto the apical sur-
face, a situation that mimics the in vivo respiratory sys-
tem’s exposure to aerosols [17]. Moreover, the epithelium 
is fed by a culture medium from the basolateral surface 
[17, 18]. Each batch is checked for tissue integrity (TEER 
measurement), as reported in the certificate of analysis. 
The product can be maintained in a homeostatic state for 
more than 1 year.
In this study, batch MP0007 was obtained from a pool 
of 14 healthy donors. Immediately after arrival at the 
laboratory, the MucilAir™ tissues were rapidly trans-
ferred to a 24-well plate previously filled with 0.7  ml of 
the specific MucilAir™ maintenance medium (Epithelix) 
at room temperature. The plates were placed overnight in 
an incubator at 37 °C, 5%  CO2 and saturated humidity.
Products
Rhinosectan® spray contains physiological saline solu-
tion, methylsulfonylmethane and xyloglucan, extracted 
from the seeds of the tamarind tree (Tamarindus indica). 
 Rhinosectan® was kindly provided by Noventure, SL 
(Spain). The product has been tested pure and diluted 
1:10 for all the assays performed except for the phagocy-
tosis assay where it was only tested undiluted.
To mimic airborne delivery, 30 μl of  Rhinosectan® was 
applied topically onto the surface of the epithelia (pipet-
ted onto the surface) and the effect was tested at two time 
points, at 15 and 60 min post-application (Fig. 1).
As negative control, saline solution (0.9% NaCl) (Euros-
pital, Trieste, Italy) was used.
Measurement of the Cilia Beating Frequency
Cilia beating frequency (CBF) and ciliated cell density 
were used to evaluate the normal functioning of the tis-
sue culture. The MucilAir™ cilia beating frequency was 
monitored at two time points (15 and 60 min) after the 
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addition of  Rhinosectan® and a saline solution as a nega-
tive control.
Morphological evaluation of the apical tissue surface 
was performed using an inverted microscope (Leica 
DMIRE2, Leica Microsystems, Germany) equipped with 
a digital camera. In order to record the morphology of 
the entire epithelium, photographs were taken. Cilia 
beating frequency was measured using a system that 
was specially designed for this purpose. The system con-
sists of three parts: a camera (Sony XCD-V60/Firewire, 
Sony Cameras, USA), a PCI card and a specific software 
package (Cilia Beating Frequency Analyser). The soft-
ware calculates the measurable areas of the images and 
data shown are coming from images with an active area 
(defined as a surface with cilia beat frequency > 3 Hz) of 
more than 90%. Data of cilia beating frequency repre-
sent the average value of thousands of active ciliated cells 
from three independent tissues, expressed as Hz.
Mucin detection
In order to measure the amount of mucin secreted on the 
surface of MucilAir™, cell monolayers were treated with 
30 µl of  Rhinosectan® spray or the negative control saline 
solution, in triplicates in a 24 well plate containing 0.7 ml 
of saline solution/well. After 15 and 60  min of treat-
ment, to collect the mucus after the product treatment, 
200  μl of NaCl-HEPES solution (buffered saline lavage) 
were applied on the apical surface of the tissue and the 
buffer containing mucus was collected immediately and 
analysed. At the different time points, the concentra-
tion of secreted mucins was measured with the Enzyme-
Linked Lectin Assay (ELLA), similar to classical ELISA 
for protein analysis. The assay relies on the interaction 
of lectins with mucin glycoproteins. It allows quantita-
tive measurement of the secreted mucins. Samples were 
applied to Nunc Maxisorp™ plates coated with Triticum 
vulgaris lectin and incubated for 30 min at 37 °C. Plates 
were blocked with bovine serum albumin (0.1%, w/v, in 
PBS) for 30  min then incubated for 30 min with horse-
radish peroxidase (HRP) labelled soybean lectin (1  µg/
ml in PBS). HRP detection was performed using BD 
OptEIA™ tetramethylbenzidine (TMB) substrate, incu-
bated at room temperature for 15 min and stopped with 
2  N  H2SO4. Mucin content was determined by optical 
absorbance (450 nm) measurement of stopped reactions.
Mucociliary clearance analysis
The effect  Rhinosectan® has on mucociliary clearance 
(MCC) was evaluated on the MucilAir™ epithelium and 
measurements of the movement of microbeads were 
performed in triplicate, as follows. First of all, as a con-
trol, mucociliary clearance was quantified following 
the movement of plugs of mucus on the apical surface. 
Then, 30  μm polystyrene microbeads (Sigma-Aldrich 
Exposure 30 μL
CILIA BEATING FREQUENCY ANALYSIS
0min 60min15 
MUCUS SECRETION and MUCOCILIARY CLEARANCE 
ANALYSIS




* PHAGOCYTOSIS ASSAY: at 15 and 60 minutes post-treatment, after 1h latex beads incubation at 37°C
Fig. 1 Study flow chart. The application of undiluted or tenfold diluted  Rhinosectan® is indicated with an arrow. Special characters show time 
points of outcome measurements at 15 and 60 min, Red Star: Cilia beating frequency; Blue Circle: Mucus secretion analysis and MCC; Green Asterisk: 
Phagocytic activity assay
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Chemie GmbH, Buchs, Switzerland) contained in 30 μl of 
 Rhinosectan® or saline solution were applied to the api-
cal surface of MucilAir™. The MCC was monitored using 
a high-speed acquisition camera (Sony XCD-SX910) con-
nected to an Axiovert 200M microscope (Zeiss, Gottin-
gen, BRD). Subsequently, 30  s movies (3 movies/insert) 
showing the movement of the small beads were taken 
and analyzed using Image Pro Plus 6.0 (Mediacy, Media 
Cybernetics, Rockville, Md., USA) imaging software. The 
first movies were acquired before the addition of the par-
ticles (control clearance) and then 15 and 60  min after 
the addition of  Rhinosectan® and the saline solution. The 
movement of the beads was tracked and the velocity of 
each particle was calculated in order to determine the 
mean speed of the particles as a measurement of muco-
ciliary clearance (μm/s).
Qualitative and quantitative phagocytosis assay
The Cayman Phagocytosis Assay Kit (IgG FITC) (Cay-
man Chemical Company, USA) employs latex beads 
coated with fluorescently-labelled rabbit-IgG as a probe 
for the identification of factors regulating the phagocytic 
process in vitro.
The assay was performed following the manufacturer’s 
instructions. Briefly, 100  μl of Latex Beads-Rabbit IgG-
FITC solution (diluted 1:10 in saline solution) was added 
simultaneously with 30  μl of  Rhinosectan® or saline 
solution to MucilAir™ cell monolayers. After incubation 
for 15 or 60 min at 37 °C, the supernatant was carefully 
aspirated and cells were gently washed with assay buffer 
to remove unbound beads. For the qualitative analysis, 
cells were analyzed directly with the inverted fluores-
cence microscope (Leica DM IL LED FLUO, Germany) 
with a10× objective, which was equipped with a filter 
capable of measuring excitation and emission at 485 and 
535  nm, respectively. For the quantitative analysis, the 
fluorescence intensity of the cells was measured in a fluo-
rescence plate reader with the appropriate filters (ex/em 
485/535  nm) (Spectrophotometer Infinite M200, Tecan, 
Switzerland). Two biological replicates for each treat-
ment (negative control and  Rhinosectan®) were used for 
fluorescence evaluation.
Statistical analysis
A descriptive analysis of quantitative data was performed. 
Mean and standard deviation values were calculated 
from  Rhinosectan® and saline-treated cell monolayers. 
Student’s T test was used to compare results between the 
two conditions. p values lower than 0.05 were considered 
significant.
Results
Rhinosectan® improves the cilia beating frequency
To test the effect of  Rhinosectan® on the stimulation 
of ciliary beating of ciliated respiratory cells, the Muci-
lAir™ epithelium was exposed to  Rhinosectan® (diluted 
or undiluted). After 15 and 60 min of treatment, the cilia 
beating frequency of the epithelium tissue was measured 
(Fig.  2). The expected activity of the untreated mon-
olayer was 7.2 ± 0.3 Hz (as reported in the certificate of 
analysis). In comparison with this value, no significant 
differences in the physiological activity of the cells were 
Fig. 2 Cilia beating frequency assay. Comparative cilia beating frequency analysis of the MucilAir™ epithelium tissue upon exposure with undiluted 
or tenfold diluted  Rhinosectan® and a saline solution during 15 and 60 min. Experiments were performed in triplicate. Asterisks show p values: 
**p < 0.01, *p < 0.05 in comparison with saline solution (Student T test)
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observed when treated with a saline solution as control 
(7.5 ± 0.4 and 7.3 ± 0.0 Hz at 15 and 60 min, respectively).
Upon application of  Rhinosectan® (diluted and undi-
luted), slight increases in cilia beating frequency were 
observed at both time points (15 and 60  min) in com-
parison with saline solution, indicating normal physi-
ological activity of the nasal epithelium in the presence 
of  Rhinosectan® (Fig.  2). With undiluted  Rhinosectan®, 
mean cilia beating frequency was 7.6 ± 0.13 Hz (p = 0.7) 
at 15  min and 8.0 ± 0.2  Hz at 60  min (p < 0.01), while 
with diluted product mean cilia beating frequency was 
8.6 ± 0.4  Hz after 15  min (p < 0.05) and 8.0 ± 0.2 after 
60  min (p < 0.01, in comparison with saline solution) 
(Fig. 2).
Exposure of  Rhinosectan® on Mucilair™ reduces mucin 
secretion
The effect of  Rhinosectan® on mucin secretion by Muci-
lAir™ tissue was measured with ELLA. After application 
of 30  µl of  Rhinosectan® or the negative control saline 
solution, the cell monolayers were incubated for 15 or 
60 min and the secreted mucin was collected and quanti-
fied. As shown in Fig. 3, no statistically significant differ-
ences were observed between saline solution and tenfold 
diluted  Rhinosectan® on the production of mucin at 
both time points of 15 and 60 min (p = 0.27 and p = 0.24, 
respectively). Of note, an important decrease (almost 
50%) in mucin concentration was observed with undi-
luted  Rhinosectan® after 15  min of exposure, in com-
parison with saline solution (171.4  ng/ml vs. 306.5  ng/
ml; p < 0.01), and also after 60 min of exposure, with an 
approximated decrease of 25% (242.7  ng/ml vs. 339  ng/
ml; p < 0.05).
Exposure of  Rhinosectan® during 60 min increases 
mucociliary clearance
The effect of  Rhinosectan® on mucociliary clearance was 
evaluated on MucilAir™ epithelium and measurements 
of the movement of plugs of mucus on the apical surface 
were assayed.
At 15  min post-exposure, similar mucociliary clear-
ance was observed with the 1/10 diluted sample of 
 Rhinosectan® (81.3 ± 1.9  μm/s) and saline solution 
(84.8 ± 2.4  μm/s), with a slight decrease with undiluted 
 Rhinosectan® (78.4 ± 1.6  μm/s; p < 0.05 vs. saline solu-
tion) (Fig. 4).
In contrast, at 60 min post-exposure, a marked increase 
in mucociliary clearance was observed with  Rhinosectan® 
(93.3 ± 2.1  μm/s with undiluted  Rhinosectan® and 
92.2 ± 1.4  μm/s with diluted  Rhinosectan®) (p < 0.01 
compared to saline solution, 80.9 ± 1.8 μm/s) (Fig. 4).
Rhinosectan® enhances the phagocytic activity of nasal 
epithelial cells
Phagocytic activity of MucilAir™ cell monolayer treated 
with  Rhinosectan® after 15 and 60 min was qualitatively 
and quantitatively evaluated (Fig. 5).
Compared to the cultures treated with saline solution, 
 Rhinosectan® treated cells showed a significant increase 
in the phagocytosis of fluorescent beads (green cells) 
Fig. 3 Mucin secretion. Effect of diluted and undiluted  Rhinosectan® on mucin secretion after exposure of the MucilAir™ epithelium to 
 Rhinosectan® during 15 and 60 min. The average of three independent experiments and standard deviation bar is shown. Asterisks show p values: 
**p < 0.01, *p < 0.05 in comparison with saline solution (Student T test)
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after 15 min of exposure (Fig. 5a). Quantification of the 
fluorescence intensity of the cultures showed a 1.86-fold 
increase of the phagocytic activity of the  Rhinosectan® 
treated cells in comparison with saline solution at 15 min 
post-exposure (p < 0.05) (Fig.  5b). At 60  min post-treat-
ment, a 1.89-fold increase in the phagocytic activity with 
 Rhinosectan® was detected, although with high variabil-
ity (Fig. 5b).
Discussion
Nowadays, there is increasing interest in assessing the 
role that the mucosal barrier plays in human health as 
it is the primary defense against pathogens, providing a 
critical transition between the external environment and 
the internal human body [1, 19].
In the case of respiratory diseases such as rhinitis, 
understanding the regulation of airway epithelial barrier 
function is opening potential new therapeutic targets [1, 
5, 6]. Allergic rhinitis is a very common disorder that is 
frequently ignored, underdiagnosed, misdiagnosed, and 
mistreated. Undertreated allergic rhinitis underlies many 
complications, exacerbates asthma and is a major factor 
in asthma development, affecting quality of life and pro-
ductivity at work or school [9, 20].
Management of rhinitis involves diagnosis, followed by 
avoidance of relevant allergens, with additional pharma-
cotherapy needed for most sufferers. According to sever-
ity, saline sprays non-sedating antihistamines (oral or 
topical, with minimally bioavailable intranasal corticos-
teroids for moderate/severe disease), possibly plus addi-
tional antihistamines or antileukotrienes can be used. 
The concept of rhinitis control is emerging, but there is 
no universally accepted definition. Where pharmaco-
therapy fails, allergen-specific immunotherapy, which 
is uniquely able to alter long-term disease outcomes, 
should be considered [20].
In this context, there is an increasing interest in the use 
of non-pharmacological measures to avoid allergens and 
other triggering factors as an integral part of the manage-
ment strategy (as recommended by the ARIA guidelines) 
[5, 7, 8] and also to avoid the secondary effects of chronic 
pharmacological measures; thereby reducing the use of 
intranasal glucocorticosteroids and antihistamines [5, 8, 
9, 21]. Although they have been established as the first-
line therapies in allergic rhinitis, there is also an ongoing 
debate regarding their potential side effects on the nasal 
structure and ciliary function [16].
In this study, we have assessed the effects of the non-
pharmacological spray  Rhinosectan®, which contains 
xyloglucan, on a MucilAir™ nasal epithelial cell culture 
model. We have demonstrated that  Rhinosectan® does 
not interfere with normal nasal functioning, for exam-
ple, in cilia beating frequency, while providing favora-
ble effects such as reducing mucin secretion, improving 
mucociliary clearance and facilitating the phagocytic 
activity of nasal epithelial cells.
We did not detect alterations in the cilia beating fre-
quency after exposure to  Rhinosectan®. Cilia beat 
frequency is one of the basic functional parameters quan-
tifying mucociliary activity and an important defense 
mechanism of the respiratory tract. For this reason, 
investigation of the influence of drugs on this parameter 
is of great importance in evaluating the tolerability and 
safety of nasally administered agents and preservatives, 
Fig. 4 Mucociliary clearance. Mucociliary clearance analysis (MCC) of the epithelium tissue upon exposure during 15 and 60 min with diluted or 
undiluted  Rhinosectan® and a saline solution. The average of three independent experiments and standard deviation bar is shown. Asterisks show 
p values: **p < 0.01, *p < 0.05 in comparison with saline solution (Student T test)
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Fig. 5 Phagocytic activity. Phagocytic activity of MucilAir™ cell monolayer treated with undiluted  Rhinosectan® after 15 and 60 min. 0.9% 
NaCl saline solution was used as a negative control. Latex Beads-Rabbit IgG-FITC solution was added to the cell monolayer at a 1:10 dilution 
simultaneously with 30 μl of  Rhinosectan® or saline solution and incubated at 37 °C for 15 or 60 min. Cells were washed with assay buffer and 
a visualized at ×10 magnification with the inverted fluorescence microscope or b the fluorescence intensity of the cells was measured in a 
fluorescence plate reader with the appropriate filter sets (ex/em 485/535 nm). a Duplicate tissues have been used for fluorescence evaluation but 
only a selection of images is reported. The first two images correspond to saline solution at baseline, the second ones to Rhinosectan at 15 min 
post-treatment and third ones to Rhinosectan at 60 min post-treatment. b The average of two independent experiments and standard deviation 
bars are shown. Asterisk show p-values lower than 0.05 (Student T test)
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present in intranasal preparations employed in the man-
agement of nasal diseases [16].
Since impairment of ciliary movement is frequently 
associated with respiratory diseases such as rhinitis, 
sinusitis, bronchitis and otitis media [22], a prerequisite 
for products used in the management of rhinitis, sinusitis 
and related allergic or chronic conditions is that agents in 
the formulation do not interfere with normal nasal func-
tioning [16].
These results are in contrast with studies showing 
interference of the ciliary movement in presence of nasal 
pharmacological agents: undiluted aqueous budesonide 
has shown to cause rapid but reversible ciliostasis [16], 
while undiluted or 50% dilution of fluticasone propion-
ate and azelastine induced an irreversible ciliostatic effect 
[16, 23]. In our study, xyloglucan and the rest of compo-
nents in the formulation of  Rhinosectan® and saline solu-
tion (the mainstay of the therapeutic armamentarium for 
patients with upper airway infections) did not alter the 
ciliary movement in the MucilAir™Nasal model at the 
time points evaluated (15 and 60  min, post-exposure), 
although further in  vitro studies should be performed 
to evaluate the effect of  Rhinosectan® during the dosing 
interval (6–8 h).
Our results are also in line with a previous study per-
formed with  Rhinosectan® in MucilAir™Nasal cells, in 
which  Rhinosectan® exhibited protective barrier proper-
ties, maintaining the location of tight junctions proteins 
and preserving the paracellular flux [5].
We also observed a significant increase in mucociliary 
clearance at 60  min post-exposure in comparison with 
saline solution. This increase was not observed at 15 min 
post-exposure, maybe due to the time required by xylo-
glucan to initiate the bioadhesion process on the mucous 
membranes (with mucin-like structure), owing to its high 
swelling capacity, which gives it its bio-protective film 
properties [1].
Mucociliary clearance removes inhaled and deposited 
particles, such as dust, allergens, bacteria and air pollut-
ants, being essentially dependent upon the unidirectional 
beating of epithelial cilia and the rheological (visco-elas-
tic) properties of mucus [16, 24]. Impairment of mucocil-
iary clearance results in the accumulation of respiratory 
secretions and reduced defenses, leading to infections 
and inflammation [25]. Mucociliary clearance thus func-
tions as a biomarker of nasal mucosal function [26].
In the case of rhinosinusitis, mucociliary clearance 
has been shown to be impaired due to both decreased 
ciliary beat frequency and altered mucus rheology [24]. 
Therefore, according to the results of this study, in the 
absence of ciliostasis, the improvement in mucociliary 
clearance together with the observed decrease in mucin 
concentration, suggests that  Rhinosectan® has optimal 
properties for use in the management of these disor-
ders. In the case, for example, of hypertonic saline solu-
tions, improvement of mucociliary clearance has also 
been observed, although a certain degree of ciliostasis 
may occur as a result of hypertonicity [24].
We also observed a significant increase in the phago-
cytic capacity after  Rhinosectan® exposure, at both 15 
and 60 min post-treatment, suggesting a positive effect 
of the spray enhancing the ability of the epithelial cells 
to display their phagocytic function by efficiently trap-
ping and removing inhaled particles and allergens.
Another important result of this study is the reduc-
tion in mucin secretion with the application of 
 Rhinosectan® spray, particularly when undiluted. 
Excessive mucus or impaired clearance contributes to 
the pathogenesis of all the common airway diseases 
[27–30]. When mucin production is increased, so that 
mucins accumulate intracellularly, and secretion of 
a large number of granules is then triggered (mucus 
hypersecretion), airway luminal occlusion can occur 
[31–33]. Additionally, persistent accumulation can lead 
to infection and inflammation by providing an environ-
ment for microbial growth.
Thus, the effect of  Rhinosectan® on mucin secre-
tion might indicate a positive role in the regulation of 
the secretion, which is crucial for essential nasal func-
tions although further studies are needed on this issue 
and taking into account that oligomeric mucins alone do 
not constitute mucus, and other mucin and non-mucin 
components must be important contributors to mucus 
organization and hence airways defense [27]. This is also 
in agreement with the results of the recent randomized, 
double-blind clinical trial performed in patients with 
rhinosinusitis, in which the application of  Rhinosectan® 
significantly improved main symptoms and reduced the 
severity of rhinosinusitis in comparison with a physiolog-
ical saline nasal spray [10].
Therefore, these results suggest that application of 
 Rhinosectan® contributes to the optimal rheological 
(visco-elastic) properties of mucus by enhancing muco-
ciliary clearance, taking into account that the balance 
between mucin production and clearance depends 
on optimal mucin quantities, the hydration state and 
periciliary fluid depth [34]. It is also important to note 
that stimulation of mucin secretion occurs with expo-
sure to irritants and pro-inflammatory compounds 
and may lead to mucus obstruction of small airways 
and increased nasal resistance. It has been observed 
that products commonly used to relieve symptoms of 
chest congestion (containing products such as cam-
phor, menthol and eucalyptus oil) can adversely affect 
mucociliary function, increasing mucin secretion and 
decreasing mucus clearance [35].
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Although more aspects deserve further research, 
as further in vivo studies and clinical trials in patients 
with rhinitis during longer periods of time (for exam-
ple during pollen seasons), the results of this study in 
the in vitro model of MucilAir™Nasal suggest that the 
application of  Rhinosectan® does not impair ciliary 
movement, enhances mucociliary clearance and facili-
tates phagocytosis, while reducing mucin secretion, 
which are optimal properties for the management of 
rhinitis and associated conditions.
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